PLSEPulse Biosciences, Inc.
$52.99+202% 1Y
$52.99
$12.6652 weeks$55.20
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+3837.7 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PLSE?
Pulse Biosciences, Inc. spent more than it took in: an operating loss of $83M on $1.2M of revenue, 12 months to Q2 2026.
$83M
Operating loss · on $1.2M of revenue · 12 months to Q2 2026
- Gross margin
- 0.25%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −43829% |
| FY2021 | −4444% |
| FY2022 | −8294% |
| FY2025 | −21983% |
Details›
- Gross margin12 months to Q2 2026
- 0.25%
- Operating margin12 months to Q2 2026
- −7008%
- Net margin12 months to Q2 2026
- −6756%
- Free cash flow margin
- −5180%
- R&D as % of revenue
- 4379%
- Revenue, trailing twelve months
- $1.2M
- Free cash flow, trailing twelve months
- −$61M
- Net income, trailing twelve months
- −$80M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #20 of 20 by RyuScore